Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes known as the "incretinmimetics". One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Licensed GLP-1 agonists:

• exenatide (Byetta), licensed in 2005 - Exenatide (Byetta, Bristol Myers Squibb) received FDA approval in 2005 and was the first GLP-1 incretin mimetic. Once-weekly exenatide, Bydureon is receiving attention due to the long-acting mechanism of action.
  
  
• liraglutide (Victoza), licensed 2010 by Novo Nordisk is another once-daily injectable GLP-1 analog Under investigation:
  
  
• albiglutide, in phase III - GlaxoSmithKline albiglutide (Syncria)
  


• taspoglutide, phase III halted Sept 2010- Taspoglutide (Roche) is a long-acting glucagon-like peptide 1 receptor agonist Semaglutide- (Novo Nordisk) is a new, acylated, LA GLP-1 analogue with a half-life of 160 h.


• Semaglutide- (Novo Nordisk) is a new, acylated, LA GLP-1 analogue with a half-life of 160 h.